Holen Sie sich die Stockscreener-App
3.28
8.38%
-0.30
Vorhandelsmarkt:
2.95
-0.33
-10.06%
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why - Benzinga
Medicus Pharma to implement 50-for-1 share consolidation to meet Nasdaq minimum bid - TradingView
Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12 - StreetInsider
Medicus Pharma Ltd. Warrant (MDCXW) Holds Flat at $0.35 Inside a Narrow Trading BandMACD Signal Stocks - https://www.dars.gov.et/
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Medicus Pharma ends standby equity purchase agreement with Yorkville - Investing.com
How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan
MDCX 8-K FilingsMedicus Pharma Ltd. SEC 8-K - Stock Titan
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com UK
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Yahoo Finance
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Canada
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com UK
FDA authorizes the next study of a skin cancer patch - Stock Titan
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - stocktitan.net
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - stocktitan.net
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - stocktitan.net
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Yahoo Finance
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
2.86%
5.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):